Foresee Pharmaceuticals has reported positive results from its Phase 3 clinical trial assessing FP-001 LMIS — a ready-to-use, testosterone-lowering treatment — in patients with advanced prostate cancer. Suppressing serum testosterone was the single-arm study’s primary goal. ... Read more